CDIP1: A Transmembrane Protein I1 as a Drug Target and Biomarker

Target Name: CDIP1

NCBI ID: G29965

CDIP1

CDIP1: A Transmembrane Protein I1 as a Drug Target and Biomarker

CDIP1 (C-type Lectin-like 1), also known as CDIP1-CLIN2, is a protein that is expressed in various cell types, including endothelial, epithelial, and mesenchymal tissues, and is involved in cell adhesion, migration, and invasion. The discovery of CDIP1 as a potential drug target and biomarker has significant implications for the development of new therapeutic approaches for various diseases.

CDIP1: Structure and Function

CDIP1 is a 21-kDa transmembrane protein that consists of an N-terminal cytoplasmic domain, a transmembrane region, and an C-terminal cytoplasmic domain. The cytoplasmic domain contains a nucleotide-binding oligomerization domain (NBD), a carboxy-terminal region, and a lysine-rich region.

CDIP1 is a member of the Integrins family, which includes proteins that are involved in cell adhesion, migration, and invasion. Integrins are a type of transmembrane protein that consists of an extracellular domain that interacts with various adhesion molecules on the cell surface, as well as an intracellular domain that interacts with co-regulated proteins.

CDIP1 plays a critical role in cell adhesion and migration, as it is involved in the formation of tight junctions and adherens junctions, which are essential for the maintenance of tissue structure and function. CDIP1 has also been shown to be involved in the regulation of cell migration, as it has been shown to promote the migration of various cell types, including cancer cells.

In addition to its role in cell adhesion and migration, CDIP1 has also been shown to play a critical role in the regulation of cell survival and proliferation. For example, CDIP1 has been shown to be involved in the regulation of cell cycle progression, as it has been shown to inhibit the G1-S transition and promote the G0-G1 transition.

CDIP1 as a Drug Target

The potential use of CDIP1 as a drug target is based on its involvement in various cellular processes that are associated with the development and progression of various diseases. One of the main reasons for the potential of CDIP1 as a drug target is its involvement in the regulation of cell adhesion, migration, and survival, which are all critical processes that are associated with the development and progression of various diseases, such as cancer, neurodegenerative diseases, and developmental disorders.

CDIP1 has been shown to interact with various signaling molecules, including TGF-β1, FGF, and Wnt, which are involved in the regulation of cell growth, differentiation, and survival. Therefore, targeting CDIP1 with small molecules or antibodies that can modulate its activity may be an effective way to treat various diseases.

In addition to its potential as a drug target, CDIP1 has also been shown to be a potential biomarker for various diseases. The expression of CDIP1 is often increased in various diseases, including cancer, neurodegenerative diseases, and developmental disorders, which may be an indication of the disease and the potential for a therapeutic approach.

CDIP1 as a Biomarker

CDIP1 has been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and survival, which are all critical processes that are associated with the development and progression of various diseases. Therefore, CDIP1 has significant potential as a biomarker for various diseases.

For example, the expression of CDIP1 has been shown to be increased in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, the levels of CDIP1 expression may be an indicator of the disease and the potential for

Protein Name: Cell Death Inducing P53 Target 1

Functions: Acts as an important p53/TP53-apoptotic effector. Regulates TNF-alpha-mediated apoptosis in a p53/TP53-dependent manner

The "CDIP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDIP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets